Related references
Note: Only part of the references are listed.A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs
Jun Hashimoto et al.
MODERN RHEUMATOLOGY (2009)
Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial
H. K. Genant et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers
Steven Young-Min et al.
ARTHRITIS AND RHEUMATISM (2007)
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab
Norihiro Nishimoto et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis - Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial
D van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2006)
The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
FC Breedveld et al.
ARTHRITIS AND RHEUMATISM (2006)
Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with Osteoarthritis and rheumatoid arthritis
N Charni et al.
ARTHRITIS AND RHEUMATISM (2005)
Presentation and analysis of data on radiographic outcome in clinical trials - Experience from the TEMPO study
D van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2005)
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy - A randomized, placebo-controlled, 52-week trial
EC Keystone et al.
ARTHRITIS AND RHEUMATISM (2004)
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
L Klareskog et al.
LANCET (2004)
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis - A randomized, controlled trial
EWS Clair et al.
ARTHRITIS AND RHEUMATISM (2004)
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
JM Bathon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Infliximab and methotrexate in the treatment of rheumatoid arthritis
PE Lipsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
